« Back Urologic Oncology: Seminars and Original Investigations

Article in Press

Recurrent seminomas: Clinical features and biologic implications

  • Avik Som

      Affiliations

    • Department of Genitourinary Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA
    • Current affiliation: The Johns Hopkins University, Baltimore, MD.
    • King Foundation Summer Scholar, The University of Texas M. D. Anderson Cancer Center, Houston, TX.
    • ,
  • Rui Zhu, Ph.D.

      Affiliations

    • Department of Genetics, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA
    • ,
  • Charles C. Guo, M.D.

      Affiliations

    • Department of Pathology, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA
    • ,
  • Eleni Efstathiou, M.D., Ph.D.

      Affiliations

    • Department of Genitourinary Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA
    • ,
  • Li Xiao, M.D.

      Affiliations

    • Department of Pathology, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA
    • ,
  • Louis L. Pisters, M.D.

      Affiliations

    • Department of Urology, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA
    • ,
  • Angabin Matin, Ph.D.

      Affiliations

    • Department of Genetics, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA
    • ,
  • Shi-Ming Tu, M.D.

      Affiliations

    • Department of Genitourinary Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1-713-563-7268; fax: ++1-713-745-1625

Received 10 March 2010 ,Revised 19 May 2010 ,Accepted 21 May 2010. Published online 07 September 2010 Corrected Proof

References 

  1. Motzer RJ, Reuter VE, Cordon-Cardo C, et al. Blood group-related antigens in human germ cell tumors. Cancer Res. 1988;48:5342–5347
  2. Srigley JR, Mackay B, Toth P, et al. The ultrastructure and histogenesis of male germ neoplasia with emphasis on seminoma with early carcinomatous features. Ultrastruct Pathol. 1988;12:67–86
  3. Mencel PJ, Motzer RJ, Mazumdar M, et al. Advanced seminoma: Treatment results, survival, and prognostic factors in 142 patients. J Clin Oncol. 1994;12:120–126
  4. Miller KD, Loehrer PJ, Gonin R, et al. Salvage chemotherapy with vinblastine, ifosfamide, and cisplatin in recurrent seminoma. J Clin Oncol. 1997;15:1427–1431
  5. Vuky J, Tickoo SK, Sheinfeld J, et al. Salvage chemotherapy for patients with advanced pure seminoma. J Clin Oncol. 2001;20:297–301
  6. Rick O, Siegert W, Schwella N, et al. High-dose chemotherapy as salvage treatment for seminoma. Bone Marrow Transplant. 2002;30:157–160
  7. Gholam D, Fizazi K, Terrier-Lacombe M-J, et al. Advanced seminoma—treatment results and prognostic factors for survival after first-line, cisplatin-based chemotherapy and for patients with recurrent disease: A single-institution experience in 145 patients. Cancer. 2003;98:745–752
  8. Hofer MD, Brown TJ, He L, et al. Identification of two molecular groups of seminomas by using expression and tissue arrays. Clin Cancer Res. 2005;11:5722–5729
  9. Gregoire M, Schopperle WM, DeWolf WC. Distinct glycoforms of a tumor specific glycoprotein, gp200, in human testis and testicular tumors. J Urol. 1995;154:275–277
  10. Rajpert-De Meyts E, Kvist M, Skakkebaek NE. Heterogeneity of expression of immunohistochemical tumor markers in testicular carcinoma in situ: pathogenetic relevance. Virchows Arch. 1996;428:133–139
  11. Giwercman A, Andrews PW, Jorgensen N, et al. Immunohistochemical expression of embryonal marker TRA-1-60 in carcinoma in situ and germ cell tumors of the testis. Cancer. 1993;72:1308–1314
  12. Yoshida SO, Imam A. Monoclonal antibody to a proximal nephrogenic renal antigen: Immunohistochemical analysis of formalin-fixed, paraffin-embedded human renal cell carcinomas. Cancer Res. 1989;49:1802–1809
  13. Kondagunta GV, Bacik J, Donadio A, et al. Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors. J Clin Oncol. 2005;23:6549–6555
  14. Mathew P, Vakar-Lopez F, Troncoso P. Protracted remission of metastatic epithelioid angiosarcoma with weekly infusion of doxorubicin, paclitaxel, and cisplatin. Lancet Oncol. 2006;7:92–93
  15. Newlands ES, Begent RH, Rustin GJ, et al. Further advances in the management of malignant teratomas of the testes and other sites. Lancet. 1983;321:948–51
  16. Bjurlin MA, August CZ, Weldon-Linne M, et al. Histologically pure stage I seminoma with an elevated beta-hCG of 4497 IU/l. Urology. 2007;70:1007;e13–1007.e15.
  17. Weissbach L, Bussar-Maatz R, Löhrs U, et al. Prognostic factors in seminomas with special respect to HCG: Results of a prospective multicenter study. Seminoma Study Group. Eur Urol. 1999;36:601–608
  18. Lachman MF, Ricci A, Pedersen C, et al. Atypical seminoma—histologic features, immunohistochemical characterization, and correlation with survival. Conn Med. 1993;57:443–449
  19. Coustan-Smith E, Mullighan CG, Onciu M, et al. Early T-cell precursor leukemia: A subtype of very high-risk acute lymphoblastic leukemia. Lancet Oncol. 2009;10:147–156

PII: S1078-1439(10)00135-3

doi: 10.1016/j.urolonc.2010.05.011

« Back Urologic Oncology: Seminars and Original Investigations

Article in Press

Article Tools

* Image Usage & Resolution